Simulations Plus Inc Stock Price, News & Analysis

Simulations Plus, Inc. (Nasdaq: SLP) has announced that CEO Shawn O’Connor will present at the Sidoti Small-Cap Investor Conference, scheduled for March 22-23, 2023. O’Connor's presentation is set for March 23, 2023, at 3:15 p.m. Eastern Time. The live webcast can be accessed via provided links and will be available for replay afterward. Simulations Plus is a leading provider of software and consulting services in the biosimulation market, supporting various pharmaceutical processes for over 25 years. For further details about the conference, visit the Sidoti website or contact Brian Siegel from Hayden IR.

Simulations Plus (Nasdaq: SLP) announced a collaborative research agreement with the Institute of Medical Biology at the Polish Academy of Sciences. This partnership aims to design new compounds targeting the RORγ/RORγT nuclear receptors using AI and machine learning through the ADMET Predictor® platform. The collaboration involves jointly owning intellectual property resulting from this research, which focuses on treating cancers associated with these receptors. The project combines expertise from both organizations to optimize drug design, enhancing opportunities for new compound development.

Simulations Plus (NASDAQ: SLP) announced the release of MonolixSuite™ version 2023R1, featuring significant upgrades to the PKanalix, Monolix, and Simulx modules. This update enhances user data input, report generation, and plotting flexibility, improving performance and interoperability. President Jonathan Chauvin emphasized the integration of user feedback for a more streamlined modeling experience. A webinar on the new features will take place on March 16, 2023, at 12:00 p.m. ET. Simulations Plus continues to serve the pharmaceutical industry with innovative biosimulation solutions.

Simulations Plus, Inc. (Nasdaq: SLP), a prominent provider of simulation software for pharmaceuticals, announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference, held virtually from March 13-15, 2023. CEO Shawn O’Connor will present on March 14, 2023, at 11:20 a.m. Eastern Time, and he will engage with investors throughout the day. A live webcast of the presentation can be accessed via their website and will be available for replay afterward.

Simulations Plus, Inc. (NASDAQ: SLP), a leader in modeling software for pharmaceutical safety, will present at the Raymond James 44th Annual Institutional Investors Conference from March 5-8, 2023, in Orlando, Florida. CEO Shawn O’Connor is scheduled to speak on March 7, 2023, at 1:40 p.m. Eastern Time and will host one-on-one meetings. Interested parties can access a live webcast and presentation on the company's Investors page post-event. Attendance is by invitation only. Simulations Plus has been serving the biosimulation market for over 25 years, offering solutions for drug discovery and regulatory submissions.

Simulations Plus (Nasdaq: SLP) has entered a new collaboration with a leading agrochemicals company to enhance the ADMET Predictor platform. This partnership aims to improve the accuracy of predicting ionization constants (pK_a) for chemical compounds by utilizing the partner's proprietary data. Dr. Robert Fraczkiewicz highlighted that this collaboration will expand chemical coverage and drive next-generation safety assessments, particularly important due to global regulations limiting animal testing. The enhancements will benefit clients across multiple industries, including chemicals and cosmetics.

Simulations Plus (NASDAQ: SLP) has launched NAFLDsym v2B Beta, a new version of its quantitative systems pharmacology modeling software aimed at enhancing treatment development for nonalcoholic steatohepatitis (NASH). This release features a faster and more intuitive interface, developed using the Julia programming language, which significantly increases simulation speeds for large datasets. Key updates include a modern GUI, integration with the Julia toolkit, and a results viewer for previously exported files. A tech talk webinar on this release is scheduled for March 14, 2023, at 11:00 a.m. Eastern Time.

Simulations Plus (Nasdaq: SLP) has launched the beta version of its DILIsym^® version X (DSX), a significant update to its quantitative systems toxicology software aimed at predicting drug-induced liver injury (DILI). This new version enhances speed and user-friendliness, supporting wider adoption among pharmaceutical companies, regulators, and academics. Key updates include a software redesign, new exemplar compounds, and improved biomarker parameters. The DILIsym modeling approach is crucial for guiding drug development decisions and avoiding costly clinical trial failures.

Simulations Plus (NASDAQ: SLP) has initiated an accelerated share repurchase (ASR) program to buy back $20 million of its common shares, part of a larger $50 million share repurchase plan approved in December 2022. This move is aimed at enhancing shareholder value and aligns with the company's updated capital allocation strategy. Funding for the ASR will come from available cash balances, and the final settlement is expected by Q3 2023. Post-ASR, $30 million will remain for additional repurchases.